Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research • 10/31/25
Strength Seen in Moderna (MRNA): Can Its 13.9% Jump Turn into More Strength?Zacks Investment Research • 10/31/25
S&P 500 Gains and Losses Today: Meta Stock Drops After Earnings; Moderna SurgesInvestopedia • 10/30/25
Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The DustInvestors Business Daily • 10/23/25
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy EndpointAccesswire • 10/22/25
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025Accesswire • 10/16/25
Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant PatientsBenzinga • 10/13/25
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology CongressAccesswire • 10/12/25
Moderna (MRNA) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 10/02/25